0001534122-14-000073.txt : 20141201
0001534122-14-000073.hdr.sgml : 20141201
20141201133333
ACCESSION NUMBER: 0001534122-14-000073
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141125
FILED AS OF DATE: 20141201
DATE AS OF CHANGE: 20141201
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cell MedX Corp.
CENTRAL INDEX KEY: 0001493712
STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000]
IRS NUMBER: 383939625
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 4575 DEAN MARTIN DRIVE, SUITE 2206
CITY: LAS VEGAS
STATE: NV
ZIP: 89103
BUSINESS PHONE: (310) 508-9398
MAIL ADDRESS:
STREET 1: 4575 DEAN MARTIN DRIVE, SUITE 2206
CITY: LAS VEGAS
STATE: NV
ZIP: 89103
FORMER COMPANY:
FORMER CONFORMED NAME: Sports Asylum, Inc.
DATE OF NAME CHANGE: 20140324
FORMER COMPANY:
FORMER CONFORMED NAME: Plandel Resources, Inc.
DATE OF NAME CHANGE: 20100608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ARNETT JEAN M
CENTRAL INDEX KEY: 0001626660
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-54500
FILM NUMBER: 141257260
MAIL ADDRESS:
STREET 1: 121 - 3989 HENNING DRIVE
CITY: BURNABY
STATE: A1
ZIP: V5C 6P8
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2014-11-25
0
0001493712
Cell MedX Corp.
CMXC
0001626660
ARNETT JEAN M
121 - 3989 HENNING DRIVE
BURNABY
A1
V5C 6P8
BRITISH COLUMBIA, CANADA
1
1
1
0
VP, Corporate Strategy
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
1250000
0
A
Common Stock
1250000
1250000
D
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
1250000
0
A
Common Stock
1250000
1250000
D
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
1250000
0
A
Common Stock
1250000
1250000
D
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
1250000
0
A
Common Stock
1250000
1250000
D
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
2500000
0
A
Common Stock
2500000
2500000
D
Stock Options (Right to Buy)
0.05
2014-11-25
4
A
0
2500000
0
A
Common Stock
2500000
2500000
D
The Options will vest upon the design and commencement of first clinical trials.
The Options will vest upon the completion of first clinical trials and delivery of final white paper for first clinical trials.
The Options will vest upon the design and commencement of second clinical trials.
The Options will vest upon the completion of second clinical trials and delivery of final white paper for second clinical trials.
The Options will vest upon the design and commencement of third clinical trials
The Options will vest upon the completion of the third clinical trials and delivery of final white paper for third clinical trials.
Options that have vested will expire 5 years after vesting. Options that have not vested will expire on 12/31/2019.
The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of any of the equity securities listed in this statement for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.
Jean M. Arnett
2014-11-25